Jump to Navigation

Forest Products Industry

Gilead Sciences (GILD) Leads Search for COVID-19 Vaccine

Forest Products IIII - Thu, 04/06/2020 - 17:21

Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]

Nikola debuts on Nasdaq, how it plans to compete with other electric truck makers

Forest Products IIII - Thu, 04/06/2020 - 17:02

Trevor Milton, Nikola founder, joins Yahoo Finance's Alexis Christoforous and Brian Sozzi, to discuss its Nasdaq debut,

Markets expert warns it's 'dangerous' for investors to 'follow the momentum play'

Forest Products IIII - Thu, 04/06/2020 - 16:44

Yahoo Finance's Alexis Christoforous and Brian Sozzi speak to Megan Horneman, Verdence Capital Advisors Director of Portfolio Strategy, about overall markets and what investors should keep a lookout for.

Nio reports record deliveries in May

Forest Products IIII - Thu, 04/06/2020 - 16:37

Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Ines Ferre break down the market action for Nio.

DaVita Sets Up Classic Pattern

Forest Products IIII - Thu, 04/06/2020 - 16:32

Keep your eyes open for new setups as the pullback could be temporary. DaVita setting up a cup with handle with 85.42 buy point. RS line lagging but if money rotates here it could be actionable.

Is It Safe to Buy American International Group (AIG) Stock Right Now?

Forest Products IIII - Thu, 04/06/2020 - 16:00

Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]

3 “Strong Buy” Penny Stocks That Could See Outsized Returns

Forest Products IIII - Thu, 04/06/2020 - 15:46

Which stocks tend to polarize market watchers? Penny stocks. Out on Wall Street, investors have strong opinions when it comes to these divisive tickers, which trade for less than $5 per share.The penny stock critics make valid points when defending their stance. Sure, the price tag may look like a steal, but the fact that shares are trading at such low levels could reflect overwhelming headwinds or weak fundamentals.That being said, the fans offer up a solid argument as well. Not only does the low price mean you get more shares for your money, but hefty returns are also on the table. Even seemingly insignificant share price appreciation can result in colossal percentage gains that other more well-known or expensive names aren’t as likely to deliver.The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps?To help with the due diligence process, we used TipRanks’ database to zero in on only the penny stocks that have received bullish support from the analyst community. We found three inhabiting the healthcare sector that are backed by enough analysts to earn a “Strong Buy” consensus rating. Not to mention each offers outsized upside potential.Clearside Biomedical (CLSD)Using its patented SCS Microinjector that targets the suprachoroidal space (SCS), Clearside Biomedical develops treatments that could potentially be capable of restoring and preserving vision for people with serious back of the eye diseases. Given the strength of its platform and its $1.91 share price, several members of the Street believe that now is the time to pull the trigger.Representing Roth Capital, analyst Zegbeh Jallah cites its technology as a key component of his bullish thesis, calling the platform “undervalued." The microinjector is able to inject fluid into the SCS, which is between the choroid and sclera, so it can be effectively absorbed by adjacent tissues. This is important as it reduces off-target delivery.To provide evidence of the device’s efficacy, Jallah points to the clinical data from the pivotal studies evaluating XIPERE, its first drug using the microinjector. “The potential of Clearside's proprietary SCS microinjector to limit off-target delivery was evident by the lower rates of elevated IOP in patients treated with SC-injected triamcinolone due to lower concentrations of the drug flowing into the anterior chamber,” the analyst commented.According to Jallah, this makes it very likely that the therapy will get the FDA’s stamp of approval in mid-2021 after the company resubmits the NDA by year end 2020. It should be noted that XIPERE is currently licensed to Bausch and Artic Vision, with CLSD also finalizing a licensing agreement with Aura in July 2019 and REGENXBIO in August 2019. The analyst argues these agreements “highlight the attractiveness of Clearside's SCS microinjector.”Looking specifically at the REGENXBIO partnership, Jallah stated, “Despite some loss of that momentum due to the pandemic and the announced pushback of XIPERE's NDA resubmission date, we are bullish that promising data from the planned Phase 2 study by REGENXBIO, and Clearside's planned Phase 1 study of suprachoroidal delivery of axitinib (CLS-AX) for wet AMD, which could provide significant upside to Clearside's valuation, and make it a strong M&A target.”To this end, Jallah rates CLSD a Buy, while setting an $8 price target. This target suggests shares could soar 319% in the next year. (To watch Jallah’s track record, click here)Do other analysts agree with Jallah? As it turns out, most do. 3 Buy ratings and a single Hold add up to a Strong Buy analyst consensus. At $6.33, the average price target indicates 231% upside potential. (See Clearside stock analysis on TipRanks)Proteostasis Therapeutics (PTI)Proteostasis Therapeutics is developing CFTR modulator combinations to provide more drug options for people with cystic fibrosis (CF). As the company gears up for the release of clinical data in Q1 2021, some analysts believe that at $1.38 per share, its price tag reflects an attractive entry point.  Writing for Cantor, analyst Kristen Kluska tells clients that PTI completed enrollment and collected rectal biopsies for the CHOICES study, which features patients with ultra-rare cystic fibrosis mutations, before COVID-19 started causing delays. Currently, samples are being stored in liquid nitrogen until the company can conduct the ex vivo testing, which may take a few weeks, and the organoids are being tested in four labs in Europe.Kluska noted, “Proteostasis is in weekly engagement with centers, and notes that timelines remain on track at this time... From our calculation, we think these timelines assume that labs will be able to re-open and complete the analysis by or around August.”Additionally, Kluska points out that data in Q1 2021 may include ppFEV1, sweat chloride and safety measures. Expounding on the implications of the data readout, she said, “We think this will be a major catalyst for PTI considering results could help frame whether these assays are predictive in determining who best responds to PTI drugs (which could ultimately frame the basis for utilizing the personalized medicine approach across the MORE trial, which patients, physicians and regulators have encouraged).”The readout will also represent the first look at the triplet data beyond 28 days, which unlike the doublet, kept demonstrating an increased benefit in ppFEV1. “We think a trial double in length of eight weeks will provide more context on the amplifier's potential. Additionally, we believe there is a lower bar for efficacy for the ultra-rate mutation population (as patients are ineligible for all approved modulators), and results could help explain how many patients show some level of benefit,” Kluska stated.With its $57.1 million in cash expected to support the company’s operations into 2H21, the deal is sealed for Kluska. In line with her optimistic take, she reiterated an Overweight rating and $4 price target. Should the target be met, a twelve-month gain of 190% could be in store. (To watch Kluska’s track record, click here) Looking at the consensus breakdown, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that PTI is a Strong Buy. The $5.50 average price target puts the upside potential at 299%. (See Proteostasis stock analysis on TipRanks)Exicure, Inc. (XCUR)Exicure develops a new class of immunomodulatory and gene regulating drugs that feature its spherical nucleic acid (SNA) architecture designed to unlock the potential of therapeutic oligonucleotides in a range of cells and tissues. Currently going for $2.72 apiece, the pros on the Street think that the share price presents investors with a unique buying opportunity.Part of the excitement surrounding XCUR is related to its Phase 2 dose expansion evaluating AST-008 in patients with advanced or metastatic Merkel cell carcinoma (MCC) or cutaneous squamous cell carcinoma (CSCC) who have progressed on a single-agent checkpoint therapy. The therapy will be used in combination with pembrolizumab in MCC or cemiplimab for CSCC. With trial sites already open and enrollment kicking off during Q2 2020, focus has locked in on XCUR ahead of its presentation of updated PD and safety data on AST-008 alone and in combination with pembrolizumab at the AACR meeting on June 22-24.Among the bulls is Ladenburg analyst Wangzhi Li. He tells clients the good news extends beyond AST-008's Phase 2 trial. IND-enabling studies of XCUR-FXN in Friedreich's Ataxia (FA), a rare autosomal recessive disorder that causes neural degeneration, especially affecting neural-muscular control, are expected to begin this calendar year. Given that there’s an estimated 5,000 patients in the U.S. and 15,000 patients worldwide suffering from FA and there aren’t any FDA-approved treatments, Li argues the therapy’s potential is significant.“We see FA as an attractive indication for SNA, given SNA's broad and extended distribution in brain and spine shown in prior studies. Exicure is also exploring additional neurological conditions, including spinocerebellar ataxia, Batten disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease,” Li explained. He also points out that XCUR will partner with Friedreich’s Ataxia Research Alliance (FARA) to advance the program.If that wasn’t enough, XCUR is collaborating with Allergan on an SNA treatment from two programs for hair loss disorders. As per the terms of the deal, XCUR will screen and identify SNA candidates against selected targets for treating hair loss, and Allergan will pay XCUR $25 million upfront, up to $725 million in milestones and mid-single digit to mid-teens royalties. In addition, preclinical R&D activities for XCUR's collaboration with Dermelix for Netherton Syndrome (NS) are progressing right on track.Based on all of the above, it’s no wonder Li reiterated his Buy recommendation. With an $18 price target, shares could climb 562% higher in the next twelve months. (To watch Li’s track record, click here) Like Li, other analysts also take a bullish approach. XCUR’s Strong Buy consensus rating breaks down into 4 Buys and zero Holds or Sells. Given the $10 average price target, the upside potential lands at 268%. (See Exicure stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Should You Be Tempted To ‘Sell’ Deere & Company (DE) Stock

Forest Products IIII - Thu, 04/06/2020 - 15:44

Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]

Warren Buffett's Berkshire Hathaway Boosts Liberty SiriusXM Stake

Forest Products IIII - Thu, 04/06/2020 - 15:40

After Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) came under the spotlight for disclosing it sold stock in Delta Air Lines Inc (NYSE: DAL), Southwest Airlines Co (NYSE: LUV) and other airlines, Warren Buffett has made a few new, lesser-known investments.What's Going On?Since the end of May, Berkshire Hathaway increased its stake in Liberty SiriusXM Group (NASDAQ: LSXMK), in 300,000 share chunks."ORTEX Analytics insider data shows that Berkshire Hathaway has since the 21st of May bought almost 4.4 million shares in Liberty Media for just over $151 million," ORTEX Analytics co-founder Peter Hillerberg told Benzinga. "Last time Berkshire Hathaway was buying Liberty Media, in May 2017, they saw a return of almost 20% in the next two months."Image showing Berkshire Hathaway's historical purchases in Liberty Sirius XM Group.Additionally, short-interest data provided by ORTEX also shows that shares on loan, an indication of how short investors are, fell sharply after Buffet's firm began buying shares of the company.Image showing Liberty Sirius XM Group short-interest data.Context And Action On May 20, Morgan Stanley lowered its price target on Liberty SiriusXM Group while maintaining an Overweight rating on the stock. The rating adjustment came alongside news that the company strengthened its balance sheet in the first quarter of 2020."We are operating in unprecedented times, impacting the Liberty portfolio across the globe. Our companies in the live event space have been working with players, teams, bands, fans, and government authorities to operate during social distancing and safely provide unique and engaging experiences," Liberty Media President and CEO Greg Maffei said in a statement on the firm's first-quarter 2020 financial results."We were pleased to complete the reattribution between Formula One Group and Liberty SiriusXM Group in April. Liberty SiriusXM now includes Live Nation, a complementary business and an established leader in the entertainment space. SiriusXM posted solid first-quarter results and the business is proving resilient. Formula One Group has a strengthened balance sheet which will enable us to enhance the F1 business and be opportunistic."To learn more about this development and get access to similar insights, click here to visit ORTEX Analytics.Photo credit: Fortune Live Media, FlickrSee more from Benzinga * Forbes, Rocket Mortgage By Quicken Loans Launch 'Under 30 Detroit Hackathon': 'Regroup, Reset And Reimagine' * Mobile Bank Varo Raises 1M To Fuel Growth, Financial Innovation * StartEngine Onboards Kevin O'Leary, Extends Equity Crowdfunding To General Public(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Bond Market Flashes Stagflation Alarm After Fed’s Gusher of Cash

Forest Products IIII - Thu, 04/06/2020 - 15:40

(Bloomberg) -- The bond market is sounding the alarm that the flood of cash that policy makers have unleashed to buoy growth in the face of the pandemic will have potentially painful consequences for the economy.The Treasuries yield curve is the steepest in three years, with long-maturity rates climbing as the Federal Reserve prints billions of dollars a week to add to its stockpile of government debt and other assets. The steepening phenomenon is typically a signal of improving growth prospects, and riskier assets such as stocks are certainly rallying. Yet some investors are more wary about what it says about inflation expectations, with U.S. activity merely giving a hint of bottoming out from what’s likely the deepest slump in living memory.The risk that the market is starting to grapple with is that in the pandemic’s wake, stagflation -- a troublesome combination of tepid growth and accelerating inflation -- takes hold in the years ahead and vexes markets as it did in the 1970s. Cash is flooding into funds that invest in inflation-protected securities, and breakeven rates, another gauge of consumer-price expectations, are ticking back higher.Not that this is all bad, necessarily. The Fed would actually welcome a move away from the deflationary angst that took hold at the peak of the market turmoil in March, as its unprecedented monetary easing is aimed at doing just that. Yet the prospect that inflation will quicken at the same time that job creation sputters is far from ideal. With most bond investors braced for low rates for years to come, the specter of yields finally taking flight could prove perilous.“The Covid-19 crisis will be remembered for many things, and among them will be the long-awaited return of inflation in developed markets,” said Oliver Harvey, a macro strategist at Deutsche Bank AG.In a world of zero rates, inflation may seem like a distant threat -- and those who worry about it are a minority in the market, with inflation prognosticators having been proven wrong time and time again over the past decade. But it may be the side effect of the pandemic cure being administered by central banks and governments.The Fed’s balance sheet alone has swelled above $7 trillion from about $4 trillion in early March, and more steps may be coming, such as yield-curve control. Expectations for such a move are contributing to the steepening push.For Scott Minerd, chief investment officer at Guggenheim Investments, the Fed’s programs propping up the corporate bond market will lead companies to become even more leveraged, reducing productivity and crimping growth.Corporations’ reliance on Fed support means the central bank will “have to continue providing liquidity to the system until inflation rates pick up to levels that probably would be viewed as unacceptable by most participants of the Fed today,” Minerd said on Bloomberg TV Wednesday. The long-run implication is “a period of stagflation.”‘Apocalypse Scenario’The steepening yield curve, coming as equities are surging, looms large on the radar of Kathryn Kaminski, chief research strategist and portfolio manager at AlphaSimplex Group. For her, it warns of growing concern about inflation, a topic she says she’s hearing more buzz about.“My apocalypse scenario -- whether or not it can happen -- in terms of where we are positioned now is clearly stagflation,” she said. “That would be a reversal of all the trends we’ve been following. I don’t think it’s a short-term scenario, but that’s the scary long-term one.”The result would be equities remaining on the front foot initially as the economy reflates, then heading lower, bond prices falling, commodities rising and dollar weakness, she said.The last time stagflation gripped the U.S. in the late 1970s, 30-year yields eventually doubled in a matter of years, on their way to a record high above 15% in the early 1980s. The long bond yields about 1.55% now, up from a historic low of just under 0.7% reached in March.Telltale SignsOthers are more sanguine about growth, but still see the makings of inflation as global supply chains get clogged.Telltale signs can be seen in the latest data. Alongside the record decline in a key measure of U.S. consumer prices in April, the cost of food at home surged 2.6% from the prior month, the most since 1974, as Americans stocked up at grocery stores. In the U.K., pet food at one point jumped 26% on an annualized basis, according to Deutsche Bank calculations.Fiscal and monetary policy stimulus “in and of itself has a very, very important inflationary dynamic to it,” said Jeffrey Rosenberg, a portfolio manager of BlackRock’s Systematic Multi-Strategy Fund. He sees inflation as a risk starting in about six months, and one that’s will be marked by a steepening curve.“The Covid crisis is first and foremost a massive, massive supply shock” which then “had morphed into a massive, massive demand shock,” he said.Even as the curve steepens, market proxies for inflation projections show investors foresee U.S. consumer prices below 2% for decades, although they’re well above their March lows. Forward inflation swap rates in the U.S. and the euro-zone, favored by policy makers for long-run inflation expectations, have also rebounded yet remain below long-term averages.BlackRock Inc.’s $20 billion iShares TIPS ETF added more than $700 million last month, the most in more than two years, data compiled by Bloomberg show.U.S. inflation markets are too pessimistic, says Mark Cabana, head of U.S. rates strategy at Bank of America Corp.“The market’s view should be intolerable at the Fed,” Cabana said. “They will have to be credible in keeping rates low to generate upside inflation risk premium. That could be highly inflationary.”He’s advising clients to wager that the gap between five- and 30-year yields will widen as a way to hedge that risk.Deglobalized, DepressedStructurally, decades of globalized supply chains that stifled inflation may be at an impasse, with economists buzzing about the potential for what’s known as re-shoring and the resulting depressed global economy. For Yale University economist Stephen Roach, this backdrop combined with the growing debt pile bodes for higher inflation in the years ahead.“When you couple the trend of offshoring to re-shoring with a likely resurgence of pent-up consumer demand if we get a vaccine, you have a lethal combination of higher costs,”’ said Roach, who famously warned about the U.S. housing bubble more than a decade ago at Morgan Stanley, among other bearish predictions.“And the job destruction occurring is set to be a lasting feature of this post-Covid world,” he said. “Without labor income from employment, the recovery is going to fall short and that is the stag part of the stagflation scenario.”(Adds market indicators in third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

ZoomInfo IPO: What You Need To Know

Forest Products IIII - Thu, 04/06/2020 - 15:19

If you're looking for fresh exposure to artificial intelligence and machine learning, this B2B database wants your capital.The IPOZoomInfo Technologies Inc. (NASDAQ: ZI) will issue 44.5 million shares on the Nasdaq under ticker "ZI," according to the firm's S-1 filing. Priced between $16 and $18, the offering represents 98.1% of outstanding shares and is expected to bring in about $921.2 million.On Thursday morning, the IPO was priced at $21 per share.The lead underwriters include JPMorgan and Morgan Stanley.The company qualifies as an emerging growth company under the U.S. JOBS Act, which exempts management from certain SEC disclosure requirements.The CompanyZoomInfo guides business-to-business sales and marketing teams with a cloud-based business-insights platform meant to "shorten sales cycles and increase win rates." The product uses predictive lead and scoring data and automated sales tools to help target customers and improve sales efficiency.It currently hosts about 202,000 paid users from 15,000 companies and delivers analytics on about 14 million targeted businesses. Management claims a total addressable market of about $24 billion with current penetration around 2%.ZoomInfo has been active since 2007. The company operated under the name DiscoverOrg until February 2019, when it acquired Zoom Information and subsequently rebranded.The FinancesIn 2019, the combined entities of DiscoverOrg and ZoomInfo recorded revenue of $293.3 million for a net loss of $78 million. The previous year saw revenue of $144.3 million for a loss of $28.6 million.Related Links:Nasdaq To Restrict Chinese Listings With New Strict IPO Requirements: ReportCarvana Rival Online Car Seller Vroom Files To Go PublicSee more from Benzinga * US Initial Jobless Claims Fall Week-Over-Week, Coronavirus 'Continues To Weigh On Businesses Of All Sizes' * Warner Music IPO: What You Need To Know * Why Shopify — And Not Zoom — Is The Stock To Chase Right Now(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Jim Cramer says this is how to profit from stocks in the pandemic

Forest Products IIII - Thu, 04/06/2020 - 14:55

Here's what the "Mad Money" host says about wise investing in the midst of COVID-19.

Södra re-elects Lena Ek as Chair of its BoD

International Forest Industries - Thu, 04/06/2020 - 13:59

Södra has re-elected Lena Ek as Chair of its Board of Directors. Kristina Alsér and Magnus Hall were elected to the Board. The Meeting also resolved to elect Kristina Alsér and Magnus Hall as new members of the Board. The number of elected Board members is nine, all with a term of one year.

Södra’s Annual General Meeting resolved to adopt the Board’s proposal to distribute profit of SEK 1,068 million ($115,086), corresponding to 43% of profit before tax. Operating profit for 2019 totalled SEK 2,582 million ($278,232). The Board had previously decided not to apply for government funding for the furlough schemes introduced by Södra during the spring.

“Södra stands strong even in unsettled times and during the pandemic, we have continued to deliver essential products and services. As an economic association, the economy of the forest estate is always central and it is important that members can share the processing profits from last year’s deliveries to our mills. It is therefore gratifying that the AGM has resolved to pay a dividend,” said Lena Ek, Chair of Södra.

The profit distribution comprises a dividend of 10% (SEK 530 million ($57.1 million) on wood deliveries, a dividend of 8% (SEK 371 million ($40 million) on contributed capital and a bonus issue of 10% (SEK 167 million ($18 million).

Founded in 1938, Södra is Sweden’s largest forest-owner association, with 52,000 forest owners as its members.

Photo: Lena Ek

The post Södra re-elects Lena Ek as Chair of its BoD appeared first on International Forest Industries.

Southwest Airlines Prices Two-Tranche $1.8 Billion Debt Offering

Forest Products IIII - Thu, 04/06/2020 - 13:47

Southwest Airlines Co. (LUV) said it has priced its public offering of $1.8 billion of debt in two tranches.The U.S. carrier will offer to sell $500 million aggregate principal amount of 4.750% notes due 2023 and $1.3 billion aggregate principal amount of 5.125% notes due 2027. The 2027 notes will be issued at par value.Southwest Airlines said it expects to use the net proceeds from the offering to repay all of its outstanding debt under its 364-day credit agreement and for general corporate purposes. Upon repayment, it will terminate the credit agreement. The offering is expected to close by June 8, 2020, subject to customary closing conditions.The U.S. carrier added that the 2023 bonds are being offered as an additional issuance of its 4.750% notes due 2023, of which it sold $750 million aggregate principal amount on May 4. The notes are part of the same class as the initial notes of that series and have identical terms, other than the issue date and issue price.Stringent travel restrictions tied to the coronavirus pandemic have brought travel demand to an almost halt, slashing the value of Southwest Airlines’ shares in half this year. U.S. airlines have been burning through billions of dollars in the first quarter incurring huge losses and implementing cost-cutting plans, as well as taking steps to shore up its cash buffers to cope with the financial fallout.Over the past month, Southwest Airlines stock has seen some relief after reporting that in the month through May 18, it recorded net positive bookings reversing net negative booking trends prevalent during most of March and April, where trip cancellations outpaced new passenger bookings.Furthermore, Southwest Airlines expects to bring down average daily cash burn in June to be in the low-$20 million compared with average daily core cash spending of $30 million to $35 million in the second quarter.Last week, five-star analyst Myles Walton at UBS lifted his rating on the stock to a Buy, saying that the U.S. carrier offers the “best risk/reward” for a recovery.Meanwhile, Cowen & Co. analyst Helane Becker reiterated a Buy rating on the shares, citing Southwest’s financial strength and leisure focus.Becker believes that looking ahead to a reopening of the aviation industry, consumers are more likely to take a short-haul domestic flight than to book a trip to Europe.“The industry may still be able to salvage some of the summer season,” Becker said.Overall, Wall Street analysts are cautiously optimistic on the stock. The 13 analyst ratings are divided between 9 Buys and 4 Holds adding up to a Moderate Buy consensus. The $40.22 average price target indicates 10% upside potential in the shares in the coming 12 months. (See Southwest Airlines stock analysis on TipRanks).Related News: S&P Cuts American Airlines’ Credit Rating To ‘B-‘ from ‘B’ On Cash Flow Deficit Concern Billionaire Investor Dan Loeb’s Fund Lists Boeing As Top Winner In May Amazon Leases 12 Boeing Cargo Aircraft To Meet Online Orders Surge More recent articles from Smarter Analyst: * AstraZeneca Seeks To Make 2 Billion Covid-19 Vaccine Doses With New Supply Deals * Ebay Lifts Quarterly Sales and Profit Forecast; Shares Jump To All-Time High * Amazon Is Mulling To Buy $2 Billion Stake In Indian Telecom Bharti Airtel * AstraZeneca Partners With Accent To Develop Novel Cancer Treatments

Trade Alert: The Independent Chairman of the Board Of Northern Oil and Gas, Inc. (NYSEMKT:NOG), Bahram Akradi, Has Just Spent US$51k Buying A Few More Shares

Forest Products IIII - Thu, 04/06/2020 - 13:19

Whilst it may not be a huge deal, we thought it was good to see that the Northern Oil and Gas, Inc. (NYSEMKT:NOG...

Louis Vuitton casts doubt over $16bn Tiffany takeover

Forest Products IIII - Thu, 04/06/2020 - 13:03

Luxury goods giant LVMH suggests its takeover for the US jeweller could be on the back burner.

Nio Rising On Record-High Monthly Deliveries, Goldman Sachs Upgrade

Forest Products IIII - Thu, 04/06/2020 - 12:59

China’s electric vehicle maker Nio Inc (NIO) has revealed that it delivered 3,436 vehicles in May 2020, representing a strong 215.5% growth year over year. Shares are now rising 3% in Thursday’s pre-market trading.The deliveries consisted of 2,685 ES6s, the company’s 5-seater high-performance premium smart electric SUV, and 751 ES8s, the company’s 7-seater high-performance premium smart electric SUV and its 6-seater variant.As of May 31, 2020, cumulative deliveries of the ES8 and the ES6 reached 42,342 vehicles, of which 10,429 were delivered in 2020, NIO said.“In May, we achieved record-high monthly deliveries in our history” cheered William Bin Li, founder and CEO of NIO. He stated that the company “will further increase our production capacity and expand our sales network to support our future growth.”Meanwhile Steven Feng, chief financial officer of NIO, added, “We are pleased to see the strong monthly deliveries despite fewer working days due to the public holiday in May. We expect to achieve the delivery goal for the second quarter 2020, while continuously improving gross margin and narrowing operating loss.”In a further bullish signal NIO rallied 19% on June 3 after the stock received an upgrade from Goldman Sachs analyst Fei Fang. This comes on the back of rating upgrades from JP Morgan and Merrill Lynch.Fang boosted the stock from hold to buy with a $6.40 price target (14% upside potential). “We believe ES6 and ES8 volume strength has transitioned from being promotion-driven to reputation-driven,” Fang told investors, adding that never before has a domestic premium Chinese auto brand had a waiting list.With NIO stock enjoying a 39% year-to-date gain, analysts have a cautiously optimistic Moderate Buy consensus and an average analyst price target of $5.70 (2% upside potential). (See Nio stock analysis on TipRanks).Related News: Lyft Rises 5% After-Hours On Strong May Performance Can Tesla Provide the Million Mile EV Battery? Top Analyst Weighs In Uber In Partnership With MoneyGram For Driver Discount During Pandemic More recent articles from Smarter Analyst: * AstraZeneca Partners With Accent To Develop Novel Cancer Treatments * Inovio Suing Suppliers Over Covid-19 Vaccine Production * S&P; Cuts American Airlines’ Credit Rating To 'B-' from 'B' On Cash Flow Deficit Concern   * FedEx Adding Temporary Surcharges As Covid-19 Pressures Mount

Analysts Have Been Trimming Their Auxly Cannabis Group Inc. (CVE:XLY) Price Target After Its Latest Report

Forest Products IIII - Thu, 04/06/2020 - 12:49

It's been a good week for Auxly Cannabis Group Inc. (CVE:XLY) shareholders, because the company has just released its...


Subscribe to ForestIndustries.EU aggregator - Forest Products Industry

by Dr. Radut